公开(公告)号：US20240358673A1

公开(公告)日：2024-10-31

申请号：US18377582

申请日：2023-10-06

申请人： Franco Cavaleri

发明人： Franco Cavaleri

IPC分类号： A61K31/352 ,  A61K9/48 ,  A61K31/19 ,  A61P3/04

CPC分类号： A61K31/352 ,  A61K9/4816 ,  A61K31/19 ,  A61P3/04

摘要： Compositions and methods for providing a person with an exogenous and therapeutically effective supply of short chain fatty acids, gallates, and (optionally) one or more ketones are disclosed. The compositions include one or more short chain fatty acids (such as butyric acid, butyrate salts, propionic acid, propionate salts, acetic acid, or acetate salts); epigallocatechin gallate (EGCG); and, optionally, one or more beta-hydroxybutyrate salts. The compositions and methods are useful for inducing weight loss, ketosis, brown adipose fat cell differentiation, and/or beta-oxidative activity in a subject.

公开(公告)号：US20240342238A1

公开(公告)日：2024-10-17

申请号：US18574665

申请日：2022-06-28

申请人： Korea University Research and Business Foundation

发明人： Min Jeong SHIN ,  In Hyeok JEONG

IPC分类号： A61K38/08 ,  A61K38/06 ,  A61K38/10 ,  A61K38/17 ,  A61P3/04 ,  A61P21/00

CPC分类号： A61K38/08 ,  A61K38/06 ,  A61K38/10 ,  A61K38/1709 ,  A61P3/04 ,  A61P21/00

摘要： The present invention relates to a peptide having obesity and muscle loss inhibitory activities, and a use thereof. The peptide has excellent effects on suppressing appetite, promoting energy metabolism, inhibiting fat accumulation, and promoting lipolysis, and inhibits muscle atrophy while promoting muscle synthesis, such that the peptide can be effectively used for the prevention or treatment of obesity and sarcopenia.

公开(公告)号：US20240336661A1

公开(公告)日：2024-10-10

申请号：US18564398

申请日：2022-06-02

申请人： University of Copenhagen

发明人： Oluf Pedersen ,  Yong Fan

IPC分类号： C07K14/195 ,  A61K38/00 ,  A61P3/04 ,  A61P3/10 ,  A61P19/00

CPC分类号： C07K14/195 ,  A61P3/04 ,  A61P3/10 ,  A61P19/00 ,  A61K38/00

摘要： The present invention relates to polypeptides derived from Ruminococcus torques, and polypeptide fragments and variants thereof useful for treatment and/or prevention of metabolic disorders, muscle disorders and injuries, and bone disorders, and host cells comprising said polypeptides, polypeptide fragments or variants thereof for use as a probiotic or as a Live Biopharmaceutical Product (LBP).

公开(公告)号：US20240325549A1

公开(公告)日：2024-10-03

申请号：US18602255

申请日：2024-03-12

申请人： Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

发明人： Nan ZHANG ,  Chunhua Jiang ,  Dongzhou Liu ,  Li Teng ,  Jiale Shen

IPC分类号： A61K47/64 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605

CPC分类号： A61K47/64 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605

摘要： The present invention relates to long-acting GLP-1/GIP dual agonist compounds having a dual agonistic effect on glucagon-like peptide-1 (GLP-1) receptor and human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to the use of said compounds in the manufacture of medicaments for treating Type II diabetes mellitus.

公开(公告)号：US20240317671A1

公开(公告)日：2024-09-26

申请号：US18731457

申请日：2024-06-03

申请人： Buck Institute for Research on Aging

发明人： Scott Michael ULRICH

IPC分类号： C07C69/675 ,  A61P3/04 ,  C12N9/20 ,  C12N11/06 ,  C12N11/087 ,  C12P7/42 ,  C12P7/52 ,  C12P7/62 ,  C12P41/00

CPC分类号： C07C69/675 ,  A61P3/04 ,  C12N9/20 ,  C12P7/42 ,  C12P7/52 ,  C12P7/62 ,  C12P41/003 ,  C12N11/06 ,  C12N11/087

摘要： In various embodiments methods of preparing hydroxybutyryl 3-hydroxybutyrate and related compounds are provided along with methods of use thereof.

公开(公告)号：US20240316157A1

公开(公告)日：2024-09-26

申请号：US18572989

申请日：2022-06-24

申请人： Gan & Lee Pharmaceuticals Co., Ltd.

发明人： Jiao JIAO ,  Zhongru GAN ,  Zhen WANG ,  Wei CHEN ,  Xi WANG ,  Yining ZHANG

IPC分类号： A61K38/26 ,  A61K9/19 ,  A61K39/395 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/22 ,  A61K47/26 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

CPC分类号： A61K38/26 ,  A61K9/19 ,  A61K39/3955 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/22 ,  A61K47/26 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

摘要： The present invention relates to a pharmaceutical combination comprising a PCSK9 inhibitor and a GLP-1 receptor agonist; The invention also relates to the use of the pharmaceutical combination in preparing drugs for treating hyperglycemia, diabetes, obesity and/or cholesterol related diseases.

公开(公告)号：US20240316073A1

公开(公告)日：2024-09-26

申请号：US18574167

申请日：2022-07-07

申请人： EPM (IP), Inc. ,  Yissum Res Dev Co of Hebrew Uni of Jerusalem Ltd.

发明人： Reshef SWISA ,  Rotem SHER ,  Ron SHAHRABANI ,  Joseph TAM

IPC分类号： A61K31/00 ,  A61P3/04 ,  A61P25/00

CPC分类号： A61K31/658 ,  A61K36/3482 ,  A61P3/04 ,  A61P25/00

摘要： The present invention provides compositions and methods for treating Prader Willi Syndrome (PWS). In particular, the present invention provides pharmaceutical compositions and formulations comprising cannabidiolic acid (CBDA) ester derivatives alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating PWS.

公开(公告)号：US20240315991A1

公开(公告)日：2024-09-26

申请号：US18415255

申请日：2024-01-17

申请人： Sanford Burnham Prebys Medical Discovery Institute

发明人： Fred LEVINE

IPC分类号： A61K31/165 ,  A61P1/16 ,  A61P3/04 ,  C12Q1/48 ,  C12Q1/6851

CPC分类号： A61K31/165 ,  A61P1/16 ,  A61P3/04 ,  C12Q1/48 ,  C12Q1/6851

摘要： Provided herein are methods for using HNF4α agonists and pharmaceutical compositions thereof for reducing body weight, maintaining body weight, reducing diet induced weight gain, reducing mitochondrial stress, treating diseases or disorders such as inflammation, diabetes, nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in a subject.

公开(公告)号：US20240309366A1

公开(公告)日：2024-09-19

申请号：US18260096

申请日：2021-12-30

申请人： Arcturus Therapeutics, Inc. ,  CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED, M.P. ,  INSTITUT D’INVESTIGACIÓ BIOMÉDICA DE GIRONA DR JOSEP TRUETA ,  UNIVERSITAT DE BARCELONA

发明人： Ramón Díaz TRELLES ,  Kiyoshi TACHIKAWA ,  Priya Prakash KARMALI ,  Rajesh MUKTHAVARAM ,  Padmanabh CHIVUKULA ,  José María MORENO-NAVARRETE ,  Aleix Gavaldá NAVARRO ,  José Manuel FERNÁNDEZ-REAL ,  Marta Giralt OMS ,  Francesc Villarroya GOMBAU

IPC分类号： C12N15/113 ,  A61K9/51 ,  A61K31/713 ,  A61P3/04

CPC分类号： C12N15/113 ,  A61K9/5146 ,  A61K31/713 ,  A61P3/04

摘要： Provided herein are compositions and methods for treating metabolic disorders, such as hepatic steatosis, adipose tissue dysfunction, and insulin resistance. Small interfering RNAs (siRNAs) targeting LPS-binding protein (LBP) that include unlocked nucleotides (UNA) and their therapeutic applications for the treatment of metabolic disorders are provided herein.

公开(公告)号：US20240301429A1

公开(公告)日：2024-09-12

申请号：US18675928

申请日：2024-05-28

申请人： RSEM, LIMITED PARTNERSHIP

发明人： PRZEMYSLAW SAPIEHA ,  FRÉDÉRICK ANTOINE MALLETTE ,  MALIKA OUBAHA ,  NORMAND BEAULIEU ,  ARIEL WILSON

IPC分类号： C12N15/113 ,  A61K31/155 ,  A61K31/7088 ,  A61K38/17 ,  A61P3/04 ,  C07K16/28

CPC分类号： C12N15/1138 ,  A61K31/155 ,  A61K31/7088 ,  A61K38/179 ,  A61P3/04 ,  C07K16/2863 ,  C07K2319/30 ,  C12N2310/111 ,  C12N2310/122 ,  C12N2310/531

摘要： Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of IRE1a as a mean to control cellular senescence and induction of the SASP. Also described are methods for treating and preventing ocular vascular diseases comprising contacting cells in an eye of a subject with a biguanide compound and ophthalmic compositions comprising a biguanide compound.